Your shopping cart is currently empty

IS20 is an agonist of prokineticin receptor 1 (PKR1). It reduces Doxorubicin-induced apoptosis and ROS production by activating the Akt or MAPK pathways. In mouse models, IS20 protects the heart from cardiovascular toxicity caused by Doxorubicin, improving survival rates and cardiac function. It does not alter the cytotoxicity and anti-tumor effects of acute Doxorubicin treatment on breast cancer cells and the MDA-MB-231 xenograft mouse model. IS20 is applicable in cancer research.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | IS20 is an agonist of prokineticin receptor 1 (PKR1). It reduces Doxorubicin-induced apoptosis and ROS production by activating the Akt or MAPK pathways. In mouse models, IS20 protects the heart from cardiovascular toxicity caused by Doxorubicin, improving survival rates and cardiac function. It does not alter the cytotoxicity and anti-tumor effects of acute Doxorubicin treatment on breast cancer cells and the MDA-MB-231 xenograft mouse model. IS20 is applicable in cancer research. |
| Molecular Weight | 387.44 |
| Formula | C23H21N3O3 |
| Cas No. | 324561-95-7 |
| Smiles | O=C(NC(=CC1=CC=C(OC)C=C1)C(=O)NCC=2C=NC=CC2)C=3C=CC=CC3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.